1. Home
  2. GANX vs ALOT Comparison

GANX vs ALOT Comparison

Compare GANX & ALOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GANX
  • ALOT
  • Stock Information
  • Founded
  • GANX 2017
  • ALOT 1969
  • Country
  • GANX United States
  • ALOT United States
  • Employees
  • GANX 25
  • ALOT N/A
  • Industry
  • GANX Biotechnology: Pharmaceutical Preparations
  • ALOT Computer peripheral equipment
  • Sector
  • GANX Health Care
  • ALOT Technology
  • Exchange
  • GANX Nasdaq
  • ALOT Nasdaq
  • Market Cap
  • GANX 79.8M
  • ALOT 78.2M
  • IPO Year
  • GANX 2021
  • ALOT N/A
  • Fundamental
  • Price
  • GANX $2.02
  • ALOT $10.15
  • Analyst Decision
  • GANX Strong Buy
  • ALOT
  • Analyst Count
  • GANX 6
  • ALOT 0
  • Target Price
  • GANX $8.00
  • ALOT N/A
  • AVG Volume (30 Days)
  • GANX 779.8K
  • ALOT 28.8K
  • Earning Date
  • GANX 11-13-2025
  • ALOT 09-09-2025
  • Dividend Yield
  • GANX N/A
  • ALOT N/A
  • EPS Growth
  • GANX N/A
  • ALOT N/A
  • EPS
  • GANX N/A
  • ALOT N/A
  • Revenue
  • GANX N/A
  • ALOT $151,593,000.00
  • Revenue This Year
  • GANX N/A
  • ALOT N/A
  • Revenue Next Year
  • GANX N/A
  • ALOT N/A
  • P/E Ratio
  • GANX N/A
  • ALOT N/A
  • Revenue Growth
  • GANX N/A
  • ALOT 0.63
  • 52 Week Low
  • GANX $1.41
  • ALOT $7.53
  • 52 Week High
  • GANX $3.19
  • ALOT $17.24
  • Technical
  • Relative Strength Index (RSI)
  • GANX 58.27
  • ALOT 46.38
  • Support Level
  • GANX $1.74
  • ALOT $9.88
  • Resistance Level
  • GANX $2.40
  • ALOT $10.48
  • Average True Range (ATR)
  • GANX 0.18
  • ALOT 0.30
  • MACD
  • GANX 0.04
  • ALOT 0.01
  • Stochastic Oscillator
  • GANX 49.72
  • ALOT 55.84

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

About ALOT AstroNova Inc.

AstroNova Inc designs, develops, manufactures, and distributes a broad range of specialty printers and data acquisition and analysis systems, including both hardware and software, which incorporate technologies to acquire, store, analyze, and present data in multiple formats sold under the QuickLabel, TrojanLabel and GetLabels brand names. Its target markets for hardware and software products include aerospace, apparel, automotive, avionics, chemicals, computer peripherals, communications, distribution, food and beverage, general manufacturing, packaging, and transportation. It has two segments, Product Identification (PI) and Test & Measurement (T&M). It generates the majority of its revenue from the PI segment that includes specialty printing systems and related supplies.

Share on Social Networks: